Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Neurology | Musculoskeletal
Multiple Sclerosis
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Clinical Research Study Available for People Diagnosed with Multiple Sclerosis
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Multiple Sclerosis Study
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for RRMS
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
MS Research Study Investigating a Novel Approach for an FDA-Approved Medication
Do you have Relapsing Remitting Multiple Sclerosis?
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for RRMS
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for RRMS
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for CIS (Pre-MS)
Relapsing forms of Multiple Sclerosis study to evaluate the safety and tolerability of two doses of an oral study drug over 24 weeks (study 7)
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
A Phase 2 study of LY2127399, an AntiBaff Human Antibody vs placebo for subjects with Relapsing Remitting Multiple Sclerosis
A Phase 3 study of PEGylated Interferon Beta-1a vs Placebo for subjects with Relapsing Remitting Multiple Sclerosis.
A Phase 3 Study to determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon-beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis.
A Phase III trial for subjects with Relapsing-Remitting Multiple Sclerosis to assess the efficacy, safety and tolerability of 40mg Glatiramer Acetate injection administered three times a week compared to placebo.
Brain and Nervous System: Research Study to Identify JC Virus in MS Patients on Disease Modifying Therapy
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for RRMS
Washington University is seeking volunteers with relapsing-remitting multiple sclerosis for a clinical trial.
Investigational Oral Medication for CIS (Pre-MS)
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Are you between the age of 18 and 65 with a diagnosis of Multiple Sclerosis?
The Dignity studies are phase III international multicenter, double-blind, randomized, placebo-controlled trials of botulinum toxin (BOTOX) in patients with spinal cord injury (SCI) or multiple sclerosis (MS); BOTOX is not yet licensed for these indications.
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Relapsing remitting multiple sclerosis
Volunteers needed for a multiple sclerosis research study
A 21 WEEK STUDY TO EVALUATE SAFETY AND EFFICACY OF ORAL FAMPRIDINE-SR IN SUBJECTS WITH MULTIPLE SCLEROSIS.
A 24-month, double-blind, randomized, multi-center, placebo-controlled, parallel-group study comparing the efficacy and safety of FTY720 1.25mg and 0.5mg administered once daily versus placebo in patients with relapsing remitting multiple sclerosis
A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon beta 1-a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing-Remitting Multiple Sclerosis (CombiRx Phase III)
A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Rituximab in Adults with Primary Progressive Multiple Sclerosis PROTOCOL: U2786g
Investigational Oral Medication for CIS (Pre-MS)
ITN020AI: A Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patient with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (MS) (STAYCIS)
Multiple Sclerosis - Adults
Multiple Sclerosis - Adults
OMEGA-Oral Megadose Corticosteroid Therapy of Acute Exacerbations in Multiple Sclerosis
The Establishment of a Patient Registry and Initiation of Related Projects of the New York State Multiple Sclerois Consortium
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for CIS (Pre-MS)
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Multiple Sclerosis: Is Your Multiple Sclerosis (MS) Still Active Despite Your Treatment?
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Looking for MS Patients for a Quality of Life Study
Multiple Sclerosis: Research Study
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
MS - Central Neuropathic Pain due to Multiple Sclerosis
MS - Central Neuropathic Pain due to Multiple Sclerosis
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for RRMS
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for RRMS
Investigational Oral Medication for RRMS
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for RRMS
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for RRMS
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for CIS (Pre-MS)
Investigational Oral Medication for RRMS
Investigational Oral Medication for CIS (Pre-MS)
